vs
Side-by-side financial comparison of ASTROTECH Corp (ASTC) and Dermata Therapeutics, Inc. (DRMA). Click either name above to swap in a different company.
ASTROTECH Corp is the larger business by last-quarter revenue ($148.0K vs $92.8K, roughly 1.6× Dermata Therapeutics, Inc.). Dermata Therapeutics, Inc. runs the higher net margin — -1853.3% vs -2653.4%, a 800.1% gap on every dollar of revenue. On growth, Dermata Therapeutics, Inc. posted the faster year-over-year revenue change (531.8% vs -43.3%).
Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.
Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing novel targeted therapies for dermatological diseases including acne, psoriasis and inflammatory skin disorders. It serves U.S. patients and healthcare providers, advancing pipeline candidates through trials to address unmet dermatological care needs.
ASTC vs DRMA — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2023
| Metric | | |
|---|---|---|
| Revenue | $148.0K | $92.8K |
| Net Profit | $-3.9M | $-1.7M |
| Gross Margin | 5.4% | — |
| Operating Margin | -2635.8% | -1953.3% |
| Net Margin | -2653.4% | -1853.3% |
| Revenue YoY | -43.3% | 531.8% |
| Net Profit YoY | 2.0% | 29.1% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.0K | — | ||
| Q3 25 | $297.0K | — | ||
| Q2 25 | $220.0K | — | ||
| Q1 25 | $534.0K | — | ||
| Q4 24 | $261.0K | — | ||
| Q4 23 | $1.1M | — | ||
| Q3 23 | $425.0K | $92.8K | ||
| Q2 23 | $414.0K | $31.1K |
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $-3.5M | — | ||
| Q2 25 | $-2.9M | — | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $-4.0M | — | ||
| Q4 23 | $-2.6M | — | ||
| Q3 23 | $-2.9M | $-1.7M | ||
| Q2 23 | $-2.3M | $-1.7M |
| Q4 25 | 5.4% | — | ||
| Q3 25 | 63.3% | — | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 59.4% | — | ||
| Q4 23 | 47.7% | — | ||
| Q3 23 | 43.1% | — | ||
| Q2 23 | 43.7% | — |
| Q4 25 | -2635.8% | — | ||
| Q3 25 | -1190.6% | — | ||
| Q2 25 | -1326.4% | — | ||
| Q1 25 | -724.2% | — | ||
| Q4 24 | -1655.6% | — | ||
| Q4 23 | -275.2% | — | ||
| Q3 23 | -784.7% | -1953.3% | ||
| Q2 23 | -659.7% | -5579.4% |
| Q4 25 | -2653.4% | — | ||
| Q3 25 | -1166.7% | — | ||
| Q2 25 | -1331.8% | — | ||
| Q1 25 | -680.3% | — | ||
| Q4 24 | -1536.0% | — | ||
| Q4 23 | -236.9% | — | ||
| Q3 23 | -685.2% | -1853.3% | ||
| Q2 23 | -560.4% | -5479.4% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.5M | $6.4M |
| Total Assets | $19.7M | $7.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | — | ||
| Q3 25 | $11.3M | — | ||
| Q2 25 | $15.1M | — | ||
| Q1 25 | $18.1M | — | ||
| Q4 24 | $21.5M | — | ||
| Q4 23 | $52.4M | — | ||
| Q3 23 | $51.7M | $6.6M | ||
| Q2 23 | $55.8M | $8.4M |
| Q4 25 | $15.5M | — | ||
| Q3 25 | $19.1M | — | ||
| Q2 25 | $22.1M | — | ||
| Q1 25 | $24.8M | — | ||
| Q4 24 | $28.1M | — | ||
| Q4 23 | $40.3M | — | ||
| Q3 23 | $42.1M | $6.4M | ||
| Q2 23 | $44.7M | $8.0M |
| Q4 25 | $19.7M | — | ||
| Q3 25 | $23.2M | — | ||
| Q2 25 | $27.0M | — | ||
| Q1 25 | $27.5M | — | ||
| Q4 24 | $31.0M | — | ||
| Q4 23 | $42.8M | — | ||
| Q3 23 | $44.6M | $7.3M | ||
| Q2 23 | $47.7M | $8.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | — |
| Free Cash FlowOCF − Capex | $-4.0M | — |
| FCF MarginFCF / Revenue | -2671.6% | — |
| Capex IntensityCapex / Revenue | 277.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-14.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-3.9M | — | ||
| Q2 25 | $-2.4M | — | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.0M | — | ||
| Q4 23 | $-1.8M | — | ||
| Q3 23 | $-3.0M | — | ||
| Q2 23 | $-1.3M | — |
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-4.4M | — | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.4M | — | ||
| Q4 23 | $-2.0M | — | ||
| Q3 23 | $-3.1M | — | ||
| Q2 23 | $-1.8M | — |
| Q4 25 | -2671.6% | — | ||
| Q3 25 | -1476.1% | — | ||
| Q2 25 | -1231.4% | — | ||
| Q1 25 | -728.1% | — | ||
| Q4 24 | -1288.5% | — | ||
| Q4 23 | -175.2% | — | ||
| Q3 23 | -723.3% | — | ||
| Q2 23 | -437.2% | — |
| Q4 25 | 277.7% | — | ||
| Q3 25 | 150.8% | — | ||
| Q2 25 | 158.2% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 122.2% | — | ||
| Q4 23 | 13.7% | — | ||
| Q3 23 | 5.6% | — | ||
| Q2 23 | 126.8% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
